Podcast: Biogen, Bitcoin levels, signals unreliable from US treasuries
Saxo Market Call
Summary: Today we delve into the FDA approval for Biogen's controversial Alzheimer drug and key next steps for the company as this approval is not final. Elsewhere, we look at technical levels for Bitcoin now that it is breaking down again and trading below the lowest daily close since January. A look at the difficulty in getting price signals from the US treasury market, European car-maker valuations, FX stories and more on the call. On today's pod were Peter Garnry on equities, Althea Spinozzi on fixed income and John J. Hardy hosting and on FX.
Follow Saxo Market Call on your favorite podcast app:
Latest Market Insights
Quarterly Outlook Q3 2022: The Runaway Train
- Central banks' attempts to kill inflation is a paradigm shift, which could end in a deep recession.
Tangible assets and profitable growth are the winnersWith US equities officially in a bear market, the big question is where and when is the bottom in the current drawdown?
Understanding the lack of investment appetite among oil majorsThe everything rally seen in recent quarters has become more uneven, as its strength is driven by commodities in short supply.
The pressure is on as the wind leaves the sailsWith cryptocurrencies in sharp decline, are we entering a crypto winter or is the bear market a healthy clean-up of the crypto space?
Why the Fed can never catch up and what turns the US dollar lower?Many other central banks are set to eventually outpace the Fed in hiking rates, taking their real interest rates to levels higher than the Fed will achieve.
Bank of Japan: Swimming against the tideThe Japanese economy has gone from the age of deflation to rapidly rising prices in no time, leaving the Bank of Japan in a pickle.
Green transformation detour and bear market hibernationWith the impending risk of global econonomic derailment, we share the five things investors need to consider in this new half year.
Crisis redux for the eurozone?Whether there's going to be a recession in Europe or not, the path towards a stable economy will be agonizing.